CLEO Appoints First Key Opinion Leader to Support US Market
Filed with ASX · · 3 pages · English
▪ KOL engagement represents a key U.S. market entry activity as a part of CLEO’s commercialisation strategy for its Pre Surgical Ovarian Cancer Test. MELBOURNE, AUSTRALIA, 19th November 2025: Ovarian Cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO or the Company) is pleased to announce the appointment of leading U.S. gynaecologic oncologist, Dr Nicholas Lambrou, as the Company
Story so far
Earlier from CLEO Diagnostics
- CLEO Significantly Expands Addressable Market
- CLEO Successfully Completes Stage 1 MDSAP Audit
- Cleo Receives Positive FDA Feedback
- Appendix 4E and 2025 Annual Report
- COV Commences Health Economic Study-Support US Market Entry
Later from CLEO Diagnostics
- Cleo Strengthens Cash Position with $1.7m R&D Tax Refund
- Trading Halt
- CLEO Raises $5m to Support U.S. Market Launch
- Quarterly activities and cashflow report
- CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics